Monbet V, Raoul W, Emond P, Gueguinou M, Lefevre A, Dolly A, Anon B, Dorval E, Chautard R, Cottet V, Lepage C, Manfredi S, Blasco H, Lecomte T, Sire O

Spectrochim Acta A Mol Biomol Spectrosc. 2026 05 8;360:128025

Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients.

Guiu B, Bailly C, Vibert E, Tlili G, Mariano-Goulart D, Edeline J, Touchefeu Y, Durand E, Blanc JF, Chalaye J, Regnault H, Bouvier A, Sergent G, Sengel C, Renaud S, Rode A, Somma C, Chevallier P, Habouzit V, Brenot-Rossi I, Dohan A, Tselikas L, DeBaère T, Manfredi S, Dieudonné A, Fowers K, Boucher E, Patel B, Vicaut E, Garin E,

EClinicalMedicine. 2026 05;95:103884

F-FDG and F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study.

Cochet A, Besson V, Bertaut A, Fouquier A, Vrigneaud JM, Bronowicki JP, Chevalier E, Heurgue A, Papathanassiou D, Blanc JF, Pinaquy JB, Vincent J, Palard-Novello X, Bourien H, Tabouret-Viaud C, Manfredi S

J Nucl Med. 2026 04 30;:

Ability of computed tomography and endoscopic ultrasound to predict pTNM of resected ampullary adenocarcinomas (AC): an analysis of the French Fédération Française de Cancérologie Digestive AC prospective cohort study.

Pellat A, Manfredi S, Truant S, Roth G, Le Malicot K, Bouché O, Piessen G, Tougeron D, Coriat R, Jary M, Schwarz L, Benoist S, Amil M, Desgrippes R, Lecomte T, Muller M, Guillet M, Locher C, Genet C, Gallois C, Taieb J, Hautefeuille V

Gastrointest Endosc. 2026 02 17;:

Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma.

Roth GS, Cros J, Neuzillet C, Barbier E, Guarssifi M, Bennacer A, Ducreux M, Muller M, Edeline J, Manfredi S, Williet N, Dusetti N, Laurent-Puig P, Ruffino V, Chanez B, Nicolle R, Taieb J, Malka D

Dig Liver Dis. 2026 01 31;:

Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.

Allaire M, Thiam EM, Amaddeo G, Bouattour M, Edeline J, Brusset B, Ziol M, Merle P, Blanc JF, Uguen T, Ganne N, Cattan S, Riachi G, Loustaud-Ratti V, Decaens T, Silvain C, Peron JM, Baron A, Pageaux GP, Oberti F, Anty R, Pascale A, Manfredi S, Bourliere M, Nousbaum JB, Heurgue A, Ollivier-Hourmand I, Lequoy M, Bronowicki JP, Villing AL, Ducournau G, Ganry O, Costentin C, Nguyen-Khac E

Liver Int. 2025 10;45(10):e70337

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer.

Lepage C, Phelip JM, Cany L, Barbier E, Manfredi S, Deguiral P, Laly M, Baconnier M, Jary M, Latrive JP, Terrebonne E, Lièvre A, Jafari M, Ben Abdelghani M, Ain JF, Breysacher G, Boillot-Benedetto I, Pelaquier A, Prost P, Ezenfis J, Rinaldi Y, Le Foll C, Berthelet O, Darut-Jouve A, Dahan L, Piche T, Lagasse JP, Bibeau F, Laurent-Puig P, Bouché O,

Ann Oncol. 2025 09 17;:

Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapy.

Nguyen-Khac E, Merle P, Ben Khadhra H, Giuliana A, Decaens T, Uguen T, Blanc JF, Ganne-Carrie N, Bouattour M, Cattan S, Silvain C, Riachi G, Peron JM, Anty R, Bronowicki JP, Baron A, Pageaux GP, Loustaud-Ratti V, Oberti F, Allaire M, Manfredi S, Ben Merabet Y, Ollivier-Hourmand I, Lequoy M, Nousbaum JB, Gelu-Simeon M, Grados L, Nahon P, Costentin C, Barbare JC, Ducournau G, Ganry O,

Eur J Gastroenterol Hepatol. 2025 09 1;37(9):1063-1077

FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trial.

Aparicio T, Turpin A, Zaanan A, de la Fouchardière C, Le Malicot K, Lonardi S, Modest DP, Wilson R, Cremolini C, Ballhausen A, Graham J, Kurreck A, Guarssifi M, Svrcek M, Laurent-Puig P, Manfredi S

Dig Liver Dis. 2025 07 28;:

TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.

Zaanan A, Bouché O, de la Fouchardière C, Le Malicot K, Pernot S, Louvet C, Artru P, Le Brun Ly V, Aldabbagh K, Khemissa-Akouz F, Lecomte T, Castanie H, Laly M, Botsen D, Roth G, Samalin E, Muller M, Breysacher G, Manfredi S, Phelip JM, Taieb J

Lancet Oncol. 2025 04 23;:

What are the outcomes for long-term survivors after esophagectomy ? - Evidence from a randomized controlled trial (FFCD9901).

Robb WB, Veziant J, Dahan L, Mornex F, Barbier E, D'Journo XB, Manfredi S, Boige V, Jary M, Christou N, Lepage C, Piessen G,

Eur J Surg Oncol. 2025 03 6;51(7):109736

Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.

Cuvelier C, Brahmi M, Sobhani I, Verret B, Grancher A, Penel N, Toulmonde M, Lahlou W, Dupuis H, Calavas L, Muller M, Watson S, Bruyat D, Poumeaud F, Chaigneau L, Manfredi S, Lecomte T, Bertucci F, Ghiringhelli F, Pracht M, Mourthadhoi F, Monceau-Baroux L, Helyon M, Kurtz JE, Roquin G, Regenet N, Vinches M, Tougeron D, Wolkenstein P, Blay JY, Bouche O, Hautefeuille V

ESMO Open. 2025 03 4;10(3):104477

First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort.

Adamus N, Edeline J, Henriques J, Fares N, Lecomte T, Turpin A, Vernerey D, Vincens M, Chanez B, Tougeron D, Tournigand C, Assenat E, Delaye M, Manfredi S, Bouché O, Williet N, Vienot A, Blaise L, Mas L, Neuzillet C, Boilève A, Roth GS

JHEP Rep. 2025 02;7(2):101279

A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort.

Roth G, Pellat A, Piessen G, le Malicot K, Schwarz L, Gallois C, Tougeron D, Hautefeuille V, Jary M, Benoist S, Amil M, Desgrippes R, Muller M, Lecomte T, Guillet M, Locher C, Genet C, Manfredi S, Bouché O, Taieb J

ESMO Open. 2024 11 18;9(12):103988

Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer.

Chautard R, Caulet M, Bouché O, Borg C, Manfredi S, Capitain O, Spano JP, Raoul W, Guéguinou M, Herault O, Ferru A, Pobel C, Sire O, Lecomte T

Dig Liver Dis. 2024 08 19;:

Trends in incidence of infrequent and frequent synchronous metastases from colorectal cancer.

Jooste V, Lepage C, Manfredi S, Bouvier AM

Dig Liver Dis. 2024 07 6;:

Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer.

Cazeneuve N, Bouché O, Leger J, Borg C, Labbe-Devilliers C, Lucidarme O, Tasu JP, Manfredi S, Aubé C, Trillaud H, Manzoni P, Marcus C, Terrebonne E, Douillard JY, Chautard R, Lobet S, Scotto B, Bleuzen A, Lecomte T

Clin Res Hepatol Gastroenterol. 2024 05 23;48(7):102380

Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases.

Aparicio T, Henriques J, Svrcek M, Zaanan A, Manfredi S, Casadei-Gardini A, Tougeron D, Gornet JM, Jary M, Terrebonne E, Piessen G, Afchain P, Lecaille C, Pocard M, Lecomte T, Rimini M, Di Fiore F, Le Brun Ly V, Cascinu S, Vernerey D, Laurent Puig P

Br J Cancer. 2024 05 14;:

Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).

Roth GS, Verlingue L, Sarabi M, Blanc JF, Boleslawski E, Boudjema K, Bretagne-Bignon AL, Camus-Duboc M, Coriat R, Créhange G, De Baere T, de la Fouchardière C, Dromain C, Edeline J, Gelli M, Guiu B, Horn S, Laurent-Croise V, Lepage C, Lièvre A, Lopez A, Manfredi S, Meilleroux J, Neuzillet C, Paradis V, Prat F, Ronot M, Rosmorduc O, Cunha AS, Soubrane O, Turpin A, Louvet C, Bouché O, Malka D

Eur J Cancer. 2024 03 13;202:114000

Adjuvant chemotherapy benefit according to T/N stage in small bowel adenocarcinoma: a large retrospective multicenter study.

Zaanan A, Henriques J, Turpin A, Manfredi S, Coriat R, Terrebonne E, Legoux JL, Walter T, Locher C, Dubreuil O, Pernot S, Vernet C, Bouché O, Hautefeuille V, Gagniere J, Lecomte T, Tougeron D, Grainville T, Vernerey D, Afchain P, Aparicio T

JNCI Cancer Spectr. 2023 09 29;:

Impact of a Tripartite Collaboration between Oncologist, Pharmacist and Diabetologist in the Management of Patients with Diabetes Starting Chemotherapy: The ONCODIAB Trial.

Paris J, Legris P, Devaux M, Bost S, Gueneau P, Rossi C, Manfredi S, Bouillet B, Petit JM, Pistre P, Boulin M

Cancers (Basel). 2023 09 13;15(18):

Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.

Falette-Puisieux M, Nault JC, Bouattour M, Lequoy M, Amaddeo G, Decaens T, Di Fiore F, Manfredi S, Merle P, Baron A, Locher C, Pellat A, Coriat R

Ther Adv Med Oncol. 2023 08 1;15:17588359231189425

Biliary tract cancers have distinct epidemiological patterns and clinical characteristics according to tumour site.

Ghiringhelli F, Jooste V, Manfredi S, Hennequin A, Lepage C, Bouvier AM

HPB (Oxford). 2023 06;25(6):693-703

Digital tool to identify and monitor regorafenib-associated hand-foot skin reactions: A proof-of-concept study protocol.

Coriat R, Sibaud V, Bourgeois V, Manfredi S, Artru P, Trouilloud I, Kremliovski M, Arvis P, Palma MD

Dig Liver Dis. 2023 05 20;:

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.

Piquemal D, Bruno R, Bournet B, Ghiringhelli F, Noguier F, Canivet C, Bertaut A, Pierrat F, Evesque L, Gamez A, Cros J, Rederstorff E, Petit E, Adnet J, Saint A, Drouillard A, Kempf E, Soularue E, Vincent J, Baumgaertner I, Hennequin A, Tournigand C, Lopez Trabada Ataz D, Bengrine L, Lepage C, Manfredi S, Afchain P, Trouilloud I, Gagnaire A, LoConte NK, Bachet JB

J Gastrointest Oncol. 2023 04 29;14(2):997-1007

Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.

Haghnejad V, Muller M, Blaise L, Gerolami R, Bouattour M, Assenat E, Manfredi S, Peron JM, Burcheri-Curatolo A, Lopez A, Ressiot E, Nahon P, Bronowicki JP

Dig Liver Dis. 2023 04 3;:

Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring.

Legris P, Bouillet B, Pâris J, Pistre P, Devaux M, Bost S, Simoneau I, Manfredi S, Drouillard A, Bastie JN, Chaix M, Massoud P, Rouland A, Aho S, Boulin M, Petit JM

Acta Diabetol. 2023 01 13;:

Should we screen for colorectal cancer in people aged 75 and over? A systematic review - collaborative work of the French geriatric oncology society (SOFOG) and the French federation of digestive oncology (FFCD).

Guittet L, Quipourt V, Aparicio T, Carola E, Seitz JF, Paillaud E, Lievre A, Boulahssass R, Vitellius C, Bengrine L, Canoui-Poitrine F, Manfredi S

BMC Cancer. 2023 01 5;23(1):17

Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies and as Risk Recurrence Factors in Stage II Colon Cancer.

Tournier B, Aucagne R, Truntzer C, Fournier C, Ghiringhelli F, Chapusot C, Martin L, Bouvier AM, Manfredi S, Jooste V, Callanan MB, Lepage C

Cancers (Basel). 2022 12 27;15(1):

Screening and management of portal hypertension in advanced hepatocellular carcinoma: a French practice survey.

Allaire M, Manfredi S, Lerosey L, Ganne-Carrié N, Thabut D

Clin Res Hepatol Gastroenterol. 2022 11 28;:102059

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.

Manfredi S, Dior M, Bouche O, Barbier E, Hautefeuille V, Guillet M, Turpin J, Bourgeois V, Helene DO, Desgrippes R, Audemar F, Molin Y, Locher C, Chatellier T, Lecomte T, Baize N, Lecaille C, Spaeth D, Goujon G, Lepage C, Tougeron D,

Cancer Med. 2022 11 16;:

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer.

Grancher A, Beaussire L, Manfredi S, Le Malicot K, Dutherage M, Verdier V, Mulot C, Bouché O, Phelip JM, Levaché CB, Deguiral P, Coutant S, Sefrioui D, Emile JF, Laurent-Puig P, Bibeau F, Michel P, Sarafan-Vasseur N, Lepage C, Di Fiore F

Front Oncol. 2022 11 10;12:973167

Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability.

Boyer C, Sefrioui D, Cohen R, Chautard R, Perrier M, Lebrun H, Goujon G, Hautefeuille V, Dior M, Walter T, Mary F, Manfredi S, Caroli-Bosc FX, Cervantes B, Coriat R, Deluche E, Zaanan A, Olivier R, Bouché O, Piessen G, Lecomte T, Louvet C, Michel P, Aparicio T, André T, Taieb J, Randrian V, Tougeron D

Dig Liver Dis. 2022 Apr 6;:

Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice.

Jooste V, Bengrine-Lefevre L, Manfredi S, Quipourt V, Grosclaude P, Facy O, Lepage C, Ghiringhelli F, Bouvier AM

Cancers (Basel). 2022 Mar 25;14(7):

Adherence to follow-up guidelines after high-risk colorectal polyp removal: a population-based study.

Dahel Y, Cottet V, Boisson C, Manfredi S, Degand T

Gastrointest Endosc. 2022 Mar 23;:

A colonoscopy quality improvement intervention in an endoscopy unit.

Palmier R, Degand T, Aho S, Lepage C, Facy O, Michiels C, Manfredi S

Sci Rep. 2022 Jan 17;12(1):817

[Epidemiology, risk factors and current screening in rectal cancer].

Bouvier AM, Manfredi S

Rev Prat. 2022 Jan;72(1):32-37

The "old" cytotoxic drugs, the basis of anti-cancer treatments.

Manfredi S

Therapie. 2021 Nov 25;:

Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in Fra

Garin E, Pinaquy JB, Bailly C, Sengel C, Mariano-Goulart D, Edeline J, Blanc JF, Bouvier A, Tordo J, Rode A, Becker S, Sefrioui D, de Baere T, Somma C, Mastier C, Goupil J, Chevallier P, Regnault H, Vibert E, Manfredi S, Vicaut E, Patel B, Boucher E, Guiu B,

Cardiovasc Intervent Radiol. 2021 Nov 18;:

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.

Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, Perrier H, Dahan L, Bourgeois V, Akouz FK, Soularue E, Ly VL, Molin Y, Lecomte T, Ghiringhelli F, Coriat R, Louafi S, Neuzillet C, Manfredi S, Malka D,

J Clin Oncol. 2021 Oct 18;:JCO2100679

Single-Breath-Hold MRI-SPACE Cholangiopancreatography with Compressed Sensing versus Conventional Respiratory-Triggered MRI-SPACE Cholangiopancreatography at 3Tesla: Comparison of Image Quality and Diagnostic Confidence.

Chevallier O, Escande H, Ambarki K, Weiland E, Kuehn B, Guillen K, Manfredi S, Gehin S, Blanc J, Loffroy R

Diagnostics (Basel). 2021 Oct 13;11(10):

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

Breton C, Aparicio T, Le Malicot K, Ducreux M, Lecomte T, Bachet JB, Taieb J, Legoux JL, De Gramont A, Benouna J, Bouché O, Boussari O, Manfredi S, Gornet JM

Eur J Cancer. 2021 Jun 12;153:40-50

Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy.

Nodari G, Popoff R, Riedinger JM, Lopez O, Pellegrinelli J, Dygai-Cochet I, Tabouret-Viaud C, Presles B, Chevallier O, Gehin S, Gallet M, Latournerie M, Manfredi S, Loffroy R, Vrigneaud JM, Cochet A

EJNMMI Res. 2021 Mar 9;11(1):24

[Management of acute pancreatitis. A literature review].

Guyot A, Lequeu JB, Dransart-Rayé O, Chevallier O, Nguyen M, Charles PE, Mouillot T, Manfredi S, Degand T

Rev Med Interne. 2021 Mar 3;:

Percutaneous Implantation of a Microcatheter-Port System for Hepatic Arterial Infusion Chemotherapy of Unresectable Liver Tumors: Technical Feasibility, Functionality, and Complications.

Chevallier O, Mvouama S, Pellegrinelli J, Guillen K, Manfredi S, Ghiringhelli F, Falvo N, Midulla M, Loffroy R

Diagnostics (Basel). 2021 Feb 26;11(3):

Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience.

Pellegrinelli J, Chevallier O, Manfredi S, Dygai-Cochet I, Tabouret-Viaud C, Nodari G, Ghiringhelli F, Riedinger JM, Popoff R, Vrigneaud JM, Cochet A, Aho S, Latournerie M, Loffroy R

Diagnostics (Basel). 2021 Jan 14;11(1):

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.

Blanc JF, Khemissa F, Bronowicki JP, Monterymard C, Perarnau JM, Bourgeois V, Obled S, Abdelghani MB, Mabile-Archambeaud I, Faroux R, Seitz JF, Locher C, Senellart H, Villing AL, Audemar F, Costentin C, Deplanque G, Manfredi S, Edeline J,

Hepatol Int. 2021 Jan 9;:

Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.

Manfredi S, Turpin A, Malka D, Barbier E, Laurent-Puig P, Zaanan A, Dahan L, Lièvre A, Phelip JM, Michel P, Hautefeuille V, Legoux JL, Lepage C, Tougeron D, Aparicio T

Dig Liver Dis. 2020 Oct;52(10):1143-1147

"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".

Taïeb J, Benhaim L, Laurent Puig P, Le Malicot K, Emile JF, Geillon F, Tougeron D, Manfredi S, Chauvenet M, Taly V, Lepage C, André T

Dig Liver Dis. 2020 May 29;:

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

Di Fiore F, Bouché O, Lepage C, Sefrioui D, Gangloff A, Schwarz L, Tuech JJ, Aparicio T, Lecomte T, Boulagnon-Rombi C, Lièvre A, Manfredi S, Phelip JM, Michel P, ,,,,,,,,

Dig Liver Dis. 2020 May 14;:

Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department.

de Grégori J, Pistre P, Boutet M, Porcher L, Devaux M, Pernot C, L Chrétien M, Rossi C, Manfredi S, Dalac S, Gueneau P, Boulin M

J Oncol Pharm Pract. 2020 Apr 16;:1078155220915763

Study of Small Intestinal Bacterial Overgrowth in a Cohort of Patients with Abdominal Symptoms Who Underwent Bariatric Surgery.

Mouillot T, Rhyman N, Gauthier C, Paris J, Lang AS, Lepers-Tassy S, Manfredi S, Lepage C, Leloup C, Jacquin-Piques A, Brindisi MC, Brondel L

Obes Surg. 2020 Feb 12;:

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).

Palmieri LJ, Mineur L, Tougeron D, Rousseau B, Granger V, Gornet JM, Smith D, Lievre A, Galais MP, Doat S, Pernot S, Bignon-Bretagne AL, Metges JP, Baba-Hamed N, Michel P, Obled S, Vitellius C, Bouche O, Saban-Roche L, Buecher B, des Guetz G, Locher C, Trouilloud I, Goujon G, Dior M, Manfredi S, Soularue E, Phelip JM, Henriques J, Vernery D, Coriat R

Oncologist. 2020 Feb;25(2):e266-e275

Small bowel adenocarcinoma: results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients.

Aparicio T, Henriques J, Manfredi S, Tougeron D, Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H, Lecaille C, Lavau-Denes S, Vernerey D, Afchain P,

Int. J. Cancer. 2020 Jan 7;:

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.

Randrian V, Adenis A, Desrame J, Barbier E, Di Fiore F, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Breysacher G, Roquin G, Louafi S, Lopez A, Louvet C, Borg C, Metges JP, Faroux R, Gaba L, Manfredi S, Tougeron D

Dig Liver Dis. 2019 Dec 30;:

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).

Oncologist. 2019 Oct 2;:

Net survival in recurrence-free colon cancer patients.

Drouillard A, Bouvier AM, Boussari O, Romain G, Manfredi S, Lepage C, Faivre J, Jooste V

Cancer Epidemiol. 2019 Jun 15;61:124-128

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).

Vendrely V, Lemanski C, Gnep K, Barbier E, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, Mirabel X, Mammar V, Cowen D, Lepage C, Aparicio T,

Radiother Oncol. 2019 Jun 8;140:84-89

Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma.

Jouve JL, Lecomte T, Bouché O, Barbier E, Akouz FK, Riachi G, Khac EN, Ollivier-Hourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM,

J. Hepatol.. 2019 May 21;:

Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.

Phelip JM, Edeline J, Blanc JF, Barbier E, Michel P, Bourgeois V, Neuzillet C, Malka D, Manfredi S, Desrame J,

Dig Liver Dis. 2018 Nov 28;:

ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort.

Aparicio T, Manfredi S, Tougeron D, Henriques J, Bouche O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Vernerey D, Afchain P

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii263

Very high-risk individuals for colorectal cancer: Local oncologic networks are critically needed!

Manfredi S, Lepage C, Faivre J

Dig Liver Dis. 2018 Sep 21;:

[Epidemiology of pancreatic cancer].

Drouillard A, Manfredi S, Lepage C, Bouvier AM

Bull Cancer. 2018 Jan;105(1):63-69

Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.

Tranquart F, Dujardin PA, Bouché O, Marcus C, Borg C, Manzoni P, Douillard JY, Labbe-Devilliers C, Terrebonne E, Smith D, Trillaud H, Capitain O, Aubé C, Spano JP, Lucidarme O, Ferru A, Tasu JP, Manfredi S, Bleuzen A, Léger J, Lecomte T

Ultraschall Med. 2017 Dec 12;:

Outcomes following polypectomy for malignant colorectal polyps are similar to those following surgery in the general population.

Lopez A, Bouvier AM, Jooste V, Cottet V, Romain G, Faivre J, Manfredi S, Lepage C

Gut. 2017 Oct 26;:

Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).

Manfredi S, Walter T, Baudin E, Coriat R, Ruszniewski P, Lecomte T, Laurenty AP, Goichot B, Rohmer V, Roquin G, Cojocarasu OZ, Lombard-Bohas C, Lepage C, Morcet J, Cadiot G

Endocrine. 2017 Jun;:

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G,

Eur. J. Cancer. 2017 May;79:158-165

Immune-checkpoint inhibition for digestive cancers.

Manfredi S, Drouillard A

Lancet Oncol.. 2017 Mar;:

Trends in net survival from esophageal cancer in six European Latin countries: results from the SUDCAN population-based study.

Launoy G, Bossard N, Castro C, Manfredi S,

Eur. J. Cancer Prev.. 2017 01;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S24-S31

Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study.

Bouvier AM, Bossard N, Colonna M, Garcia-Velasco A, Carulla M, Manfredi S,

Eur. J. Cancer Prev.. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S63-S69

Trends in net survival from rectal cancer in six European Latin countries: results from the SUDCAN population-based study.

Lepage C, Bossard N, Dejardin O, Carmona-Garcia MC, Manfredi S, Faivre J,

Eur. J. Cancer Prev.. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S48-S55

Colorectal cancer care in elderly patients: Unsolved issues.

Aparicio T, Pamoukdjian F, Quero L, Manfredi S, Wind P, Paillaud E

Dig Liver Dis. 2016 Oct;48(10):1112-8

Early Gastric Cancer: Trends in Incidence, Management, and Survival in a Well-Defined French Population.

Chapelle N, Bouvier AM, Manfredi S, Drouillard A, Lepage C, Faivre J, Jooste V

Ann. Surg. Oncol.. 2016 Oct;23(11):3677-83

Small Bowel Adenocarcinoma.

Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR

Gastroenterol. Clin. North Am.. 2016 09;45(3):447-57

Frequency of and risk factors for the surgical resection of nonmalignant colorectal polyps: a population-based study.

Le Roy F, Manfredi S, Hamonic S, Piette C, Bouguen G, Riou F, Bretagne JF

Endoscopy. 2016 Mar;48(3):263-70

Incidence and patterns of late recurrences in colon cancer patients.

Bouvier AM, Launoy G, Bouvier V, Rollot F, Manfredi S, Faivre J, Cottet V, Jooste V

Int J Cancer. 2015 Nov 1;137(9):2133-8

Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma.

Blay C, Chiforeanu DC, Boucher E, Cabillic F, Desgrippes R, Leconte B, Perrin C, Manfredi S, Audrain O, Meunier B, Edeline J

Acta Oncol. 2015 Nov;54(10):1833-5

Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues.

Brieau B, Lepère C, Walter T, Lecomte T, Guimbaud R, Manfredi S, Tougeron D, Desseigne F, Lourenco N, Afchain P, El Hajbi F, Terris B, Rougier P, Coriat R

Medicine (Baltimore). 2015 Oct;94(42):e1864

Frequency and efficacy of additional investigations following incomplete colonoscopies: A population-based analysis.

Bollart AS, Manfredi S, Piette C, Bretagne JF

Dig Liver Dis. 2015 Aug;47(8):720-5

[Screening and prevention of colorectal cancer].

Faivre J, Manfredi S

Rev Prat. 2015 06;65(6):774-8

FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.

Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R, Terrebonne E, De La Fouchardière C, Manfredi S, Solub D, Lécaille C, Thirot Bidault A, Carbonnel F, Taieb J

Ann. Surg. Oncol.. 2015 Jan;22(1):295-301